U.S. Markets closed

  • S&P 500

    4,109.31
    +58.48 (+1.44%)
     

  • Dow 30

    33,274.15
    +415.12 (+1.26%)
     

  • Nasdaq

    12,221.91
    +208.43 (+1.74%)
     

  • Russell 2000

    1,802.48
    +34.10 (+1.93%)
     

  • Crude Oil

    75.70
    +1.33 (+1.79%)
     

  • Gold

    1,987.00
    -10.70 (-0.54%)
     

  • Silver

    24.24
    +0.25 (+1.03%)
     

  • EUR/USD

    1.0847
    -0.0062 (-0.5640%)
     

  • 10-Yr Bond

    3.4940
    -0.0570 (-1.61%)
     

  • Vix

    18.70
    -0.32 (-1.68%)
     

  • GBP/USD

    1.2332
    -0.0058 (-0.4686%)
     

  • USD/JPY

    132.7970
    +0.1080 (+0.0814%)
     

  • BTC-USD

    28,352.85
    -38.73 (-0.14%)
     

  • CMC Crypto 200

    621.79
    +7.58 (+1.23%)
     

  • FTSE 100

    7,631.74
    +11.31 (+0.15%)
     

  • Nikkei 225

    28,041.48
    +258.55 (+0.93%)
     

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2022 Earnings Call Transcript

Insider Monkey Transcripts
·7 min read

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2022 Earnings Call Transcript November 14, 2022

Achieve Life Sciences, Inc. misses on earnings expectations. Reported EPS is $-1.35 EPS, expectations were $-1.13.

Operator: Good day, ladies and gentlemen, and welcome to Achieve Life Sciences Third Quarter 2022 Earnings Conference Call. All lines have been placed on a listen-only mode. And the floor will be open for questions and comments following the presentation. At this time, it is my pleasure to turn the floor over to your host Nicole Jones, CG Capital Investor Relations. Ma'am, the floor is yours.

Photo by Julia Koblitz on Unsplash

Nicole Jones : Thank you, operator. On today's call from Achieve we have John Bencich Chief Executive Officer; and Jerry Wan Principal Accounting Officer. Achieve management will be available for Q&A after the prepared remarks. I'd like to remind everyone that today's conference call contains forward-looking statements based on current expectations. These statements are only predictions and actual results may vary materially from those projected. Please refer to Achieve document available on our website and filed with the SEC concerning factors that could affect the company. I'll now turn the call over to John.

John Bencich: Thank you, Nicole and thanks everyone for joining us today. It was yet again a busy and exciting quarter for Achieve. As we continue to advance cytisinicline through the clinic and closer to becoming the first new prescription treatment for nicotine dependence in nearly two decades. In September, we announced completion of target enrollment in our confirmatory Phase III ORCA-3 trial for smoking cessation. And just last week we announced the earlier-than-expected completion of enrollment in our Phase II ORCA-V1 trial for nicotine e-cigarette or vaping cessation. As a reminder, the ORCA-3 trial is the second and final randomized Phase III trial required for FDA submission and ultimately marketing authorization in the US.

The design mirrors that of the previous ORCA-2 trial that read out with overwhelmingly positive results earlier this year. Both trials were designed to evaluate the smoking cessation efficacy, safety and tolerability of 3-milligram cytisinicline dosed three times daily over a period of either 6 weeks or 12 weeks compared to placebo. The trials also share the same primary endpoint to evaluate smoking abstinence during the last four weeks of treatment which is the FDA's approvable endpoint for smoking cessation medications. The outcome of ORCA-2 further enhanced our belief that cytisinicline if approved has strong potential to become the new gold standard for the treatment of nicotine dependence. With single-digit rates of adverse events cytisinicline side effect profile is substantially better than what has been seen in currently available treatments.

From an efficacy perspective, the odds ratios we observed in ORCA-2 were unprecedented with six times to eight times higher odds of quitting at the end of treatment compared to placebo. Additionally, our quit rates were impressive despite the highly addictive study population and the execution of the trial during a pandemic. We hope to see similar results from ORCA-3 and look forward to sharing those with you in the second quarter of 2023. Vaping continues to be an important topic on a global scale, particularly with the alarming rate of adolescent users and new data reporting the potential harmful impacts to cardiovascular and respiratory health. The CDC released data last week indicating more than 2.5 million high school and middle school students were current users of e-cigarettes in the US alone.

There are also more than 11 million adult users of nicotine vape products in the US and no treatments are currently approved specifically for vaping cessation. We pursued the ORCA-V1 trial with the expectation that cytisinicline would be of interest to this growing and underserved population. The swift recruitment of ORCA-V1 appears to reinforce our assumptions of the demand for treatment within this population. Recruiting at only five clinical trial sites, ORCA-V1's target enrollment of 150 subjects was completed in roughly four months. Regarding the design ORCA-V1 will evaluate 12 weeks of cytisinicline versus placebo. As with the other ORCA trials all participants will receive behavioral support throughout the study. The primary objective will be to evaluate for successful nicotine vaping cessation defined as weekly abstinence for the last four weeks of treatment with cotinine levels as biochemical confirmation of abstinence.

Top-line data for ORCA-V1 is also expected to be reported in the second quarter of 2023. With the two trial enrollment milestones behind us, we turn our attention to three key priorities over the coming months. First, continuous engagement with the ORCA-3 and ORCA-V1 clinical trial sites and our third-party clinical research organization to, ensure data reporting accuracy and adherence to time lines. Second, extensive preparations to support an NDA filing in the U.S., post successful ORCA-3 trial results, including the completion of the remaining supportive trials required for filing. Third, commercial readiness including, launch preparedness activities and partnering discussions with interested parties who also believe in the immense potential of cytisinicline.

Also, as part of our commercial readiness objective, we continue to work closely with our manufacturing partner Sopharma, to ensure adequate commercial capacity at launch. As we announced today, Sopharma recently invested more than €3 million to complete the build-out of a new dedicated cytisinicline API purification suite and its primary manufacturing plant in Sofia. The new API suite complements Sopharma's capacity to produce nearly three billion tablets annually. I would now like to turn the call over to Jerry, for the third quarter financial update.

See also 10 Best Widow and Orphan Stocks To Buy and Jim Cramer's Comeback Stocks.

Jerry Wan: Thank you, John. I will be providing an update on our cash position as of September 30th 2022 and reviewing our operating expenses for the third quarter. As of September 30th 2022, the company's cash, cash equivalents, short-term investments and restricted cash were $18.2 million, compared to $43 million as of December 31st 2021. Our cash forecast includes reimbursements from the awarded $2.5 million grant, received from the NIH to support the Phase 2 ORCA-V1 trial, to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use. As a reminder, approximately half of the cost from the, ORCA-V1 trial are funded through the grant from the NIH. With respect to our statement of operations, net loss increased to $13.1 million for the quarter ended September 30th 2022, compared to $6.7 million for the same quarter of 2021.

Net loss for the nine months ended September 30th 2022 increased to $31.1 million, compared to $26 million for the same period of 2021. Operating expenses increased in the third quarter, with the achievement of targeted enrollment in our ORCA-3 trial and initiation and enrollment in our ORCA-V1 trial. We expect our quarterly operating expenses will remain elevated in the fourth quarter of this year before reducing in the first half of 2023, as the ORCA-3 and ORCA-V1 trials reach completion. That concludes my financial remarks. And I will now turn the call back over to John.

John Bencich: Thanks, Jerry. 2022 has been a pivotal year for Achieve, with key highlights being the successful Phase 3 trial results and completing enrollment in two other important studies. We are pleased that we continue to deliver on our milestones and the commitments we have made to bringing forward this important new treatment. Smoking and nicotine addiction directly impacts more than one billion people around the globe. In the U.S. alone, there remain more than 30 million people who smoke and nearly 0.5 million people die each year, due to smoking-related illnesses. In an analysis, we recently conducted with current smokers who want to quit, 80% overall, stated they would be interested in a new smoking cessation products.

In the segment we believe will be most appropriate for cytisinicline, 93% desired something new. The current treatments that are available have a high dissatisfaction rating for both smokers and prescribers and new options are long overdue. More needs to be done to help people who want to quit and to improve and extend their lives. We believe we have a unique opportunity and responsibility to make a real difference with cytisinicline. Again, thanks all for your continued support and joining us today. I'd now like to turn the call over to the operator, and open the line for questions.

To continue reading the Q&A session, please click here.

Recommended Stories

  • Seeking at Least 8% Dividend Yield? Goldman Sachs Suggests 2 Dividend Stocks to Buy

    One thing is certain in the stock markets lately: their inherent uncertainty is taking charge, and high volatility is here to stay. For months, investors and economists have worried about the recessionary effects of the Federal Reserve’s anti-inflationary interest rate hikes – but the recent bank crisis has added another layer of concern to an already tumultuous situation. Now, we’re dealing with the fallout from that crisis, and inflation and interest rates both remain high. It’s a textbook cas

  • Schwab Hit by Worst Month Since 1987 Amid Cash Sorting Woes

    (Bloomberg) -- Charles Schwab Corp.’s worst month in more than 35 years has sparked a debate among analysts as to whether the brokerage giant has been unfairly punished by investors amid growing fears about the US banking sector.Most Read from BloombergParents Are Paying Consultants $750,000 to Get Kids Into Ivy League SchoolsGlobal Food Supply Risks Rise as Key Traders Leave RussiaTrump Faces Fingerprints, Mug Shot After Dramatic IndictmentSchwab Hit by Worst Month Since 1987 Amid Cash Sorting

  • US Power Plant Firm Goes Bankrupt After Winter Storm Penalties

    (Bloomberg) -- Lincoln Power LLC, the owner of two Illinois power plants, filed for bankruptcy after its financial strain was exacerbated by nearly $39 million in penalties levied by the biggest US electric-grid operator. Most Read from BloombergParents Are Paying Consultants $750,000 to Get Kids Into Ivy League SchoolsGlobal Food Supply Risks Rise as Key Traders Leave RussiaTrump Faces Fingerprints, Mug Shot After Dramatic IndictmentSchwab Hit by Worst Month Since 1987 Amid Cash Sorting WoesPut

  • A $200,000 Annuity Will Pay Out This Much a Month

    An annuity can be an appealing option to build your retirement nest egg. Adding guaranteed retirement income to your retirement can give you financial stability. But the exact amount that you'll get from an annuity each month will vary. Let's … Continue reading → The post How Much Does a $200,000 Annuity Pay Per Month? appeared first on SmartAsset Blog.

  • Procrastinators, Rejoice: The 6.89% I bonds Will Beat the Old 9.62% Bonds in Just 4 Years

    With a yield of 9.62%, the recently expired Series I bond was understandably popular. With interest rates rising, bond funds are down this year and banks continue to offer miserly rates on deposit accounts. So it's no wonder that a … Continue reading → The post It Pays to Procrastinate: The New 6.89% I bonds Will Beat the Old 9.62% Bonds in Just 4 Years appeared first on SmartAsset Blog.

  • The Charles Schwab Corporation (SCHW) Stock Sinks As Market Gains: What You Should Know

    The Charles Schwab Corporation (SCHW) closed the most recent trading day at $52.38, moving -0.17% from the previous trading session.

  • Altria Lays Out a Transition to Smokeless Products. But It Begins With the Dividend.

    The biggest cigarette company in the U.S. acknowledges that it has to move toward smokeless products. But to hold its shareholder base, it also knows it has to grow an already rich dividend.

  • Baby Boomers, You Need This Much Money to Retire Comfortably

    The Baby Boomer generation is reaching retirement age in record numbers. With more Boomers retiring on a daily basis, it helps to understand how prepared they are to leave their jobs for good. In this article, we’ll discuss the average … Continue reading → The post Average Retirement Savings for Baby Boomers appeared first on SmartAsset Blog.

  • 7 Dividend Stocks for Uncertain Economic Times

    Treasuries aren't the only refuge in a slowdown. Dividend names also "can provide a margin of safety," says UBS.

  • Nomura Says US Money Supply Plunge Is ‘Elephant in the Room’ for Markets

    (Bloomberg) -- A Nomura Holdings Inc. strategist is warning that investors are overlooking a crucial clue as they grapple with the path of US inflation and the Federal Reserve’s response. Most Read from BloombergTrump Faces Fingerprints, Mug Shot After Dramatic IndictmentWorld’s Top-Rated Airport Sees Immigration System RestoredHow King Charles Got Thrown Into Disney’s Fight With Florida Governor DeSantisTrump to Be Arraigned Next Week After Historic IndictmentStocks Rally as Traders Eye Peak Ra

  • Soaring Auto Loan Rates Are the Latest Roadblock for Car Sales

    (Bloomberg) -- Just when it seemed like things were getting back to normal at Rhett Ricart’s Columbus, Ohio, car dealerships — after pandemic-induced inventory shortages and runaway price inflation — a new obstacle emerged to keep buyers from closing the deal: soaring interest rates on auto loans.Most Read from BloombergParents Are Paying Consultants $750,000 to Get Kids Into Ivy League SchoolsGlobal Food Supply Risks Rise as Key Traders Leave RussiaTrump Faces Fingerprints, Mug Shot After Drama

  • Three Stocks Turn $10,000 To $25,265 In Just 3 Months

    Investors enjoyed a small S&P 500 rally in March. But there were much more lucrative places to put money in the month.

  • Japan's Toyota hands St Petersburg plant over to Russian state

    MOSCOW (Reuters) -Russia and Toyota said on Friday that the Japanese carmaker's factory in St Petersburg had been handed over to state entity NAMI, with Moscow snapping up more assets from global automakers leaving Russia over the conflict in Ukraine. "Toyota's production site in St Petersburg has... been transferred to the state," Russia's Ministry of Industry and Trade said in a statement. The company said in September it had decided to stop vehicle production in Russia due to the interruption in supplies of key materials and parts.

  • Virgin Orbit’s sudden collapse is the latest in a series of high-risk failures by Richard Branson

    The satellite deployment startup founded by Branson is letting go of the bulk of its staff, citing an “inability to secure meaningful funding.”

  • How to make $100,000 or more and pay no income taxes

    Here’s how to earn a six-figure income and pay no income taxes on it – totally legally.

  • The Newest ‘Bubble’ Is in Money-Market Funds

    People are rushing into money-market funds. Total assets held in money-market funds, which are investment vehicles that buy cash-like securities such as short-term Treasury bills, recently reached close to $5.5 trillion, according to RBC. Earlier this year, money-market fund assets stood at roughly $4.5 trillion, a level at which people stopped pouring more money into those funds a few times in the past few years, opting instead to buy other assets like stocks.

  • Dow Jones Rises 150 Points After Cool Inflation Data; 6 Stocks To Buy And Watch

    The Dow Jones rose Friday after key inflation data, with the release of the PCE price index, the Fed's preferred measure of inflation.

  • Here’s What Retirement Looks Like in America in Six Charts

    Americans spend decades saving for retirement, never quite sure how much is enough or what sort of life that money will ultimately buy. To benchmark your retirement plans—including your savings and spending and how you spend your time—one place to start is by looking at how your numbers stack up against Americans overall. The biggest source of retirement income for many Americans is the nest egg built up during their careers.

  • Cheap Stocks To Buy: Should You Watch These 5 Growth Stocks?

    Regardless of what stage of the market cycle we're in, some folks never tire of searching for cheap stocks to buy. If it has thin trading volume, the fund manager will have an awfully tough time accumulating shares — without making a big impact on the stock price. IBD research also finds that dozens, if not hundreds, of great stocks each year do not start out as penny shares.

  • How Much Is a Decent Retirement Home Going to Cost Me?

    A retirement home is a private facility that offers seniors care and support. These facilities typically have amenities and services that cater to the needs of seniors, including meal preparation, housekeeping, medical care and social activities. Here's a breakdown of … Continue reading → The post Retirement Home: Cost and Service Guide appeared first on SmartAsset Blog.